Anbio Biotechnology (NNNN)
The company now
Anbio Biotechnology is classed by the SEC under In Vitro & In Vivo Diagnostic Substances (industry code 2835), based in Frankfurt Am Main, DE. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $8.6 million and a profit of $6.4 million (its filed statements).
From its filings and filed figures; the desk's account of it is not written yet.
Where the revenue comes from
fiscal 2025, as filedRevenue by region, fiscal 2025
| Region | Fiscal 2025 | Fiscal 2024 | Share of revenue |
|---|---|---|---|
| European Union | $5.2M | $5.6M | 59.6% |
| Asia Pacific | $1.5M | $509,168 | 17.6% |
| Other Regions | $1.4M | $472,380 | 16.3% |
| North America | $296,199 | $110,508 | 3.4% |
| South America | $269,538 | $1.5M | 3.1% |
As tagged in its annual report (Form 20-F, filed Apr 7, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.
The desk's written account of this company, its Past, Present and Future, is not on file yet.
How the company works
The desk has not read this company's annual report yet.
The record in brief
The desk has not written this company's report yet.